Navigation Links
Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs
Date:2/24/2009

PRINCETON, N.J., Feb. 24 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, has announced the appointment of Dr. Marcel Rozencweig as Senior Executive Vice President for Clinical Affairs. Prior to joining Sopherion, Dr. Rozencweig was a key Clinical Development Consultant to the Company and a member of the Sopherion Protocol Development Team for Myocet.

"I am excited to continue to contribute to the development of Myocet," said Dr. Rozencweig. "Myocet has the potential to be a valued addition to the first-line treatment regimen for metastatic breast cancer, particularly in patients with HER-2 overexpression."

Dr. Rozencweig was previously with GPC-Biotech since 2001. He has 18 years of experience with Bristol-Myers Squibb, where he held several senior leadership positions in drug development and strategic planning, including Vice President, Oncology, Infectious Diseases and Immunology Clinical Research; and Vice President, Strategic Planning and Portfolio Management.

"Dr. Rozencweig's world-renowned experience in oncology drug development is an ideal fit for Sopherion as we move Myocet forward," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "His many achievements include significant contributions leading to the FDA approval of 11 drugs, mostly anticancer treatments, including the blockbusters Taxol(R) and Paraplatin(R) (carboplatin)."

Dr. Rozencweig is an Adjunct Associate Professor of Medicine at New York University and has authored or co-authored more than 200 scientific publications.

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patien
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cell Therapeutics to Resume Trading on MTA and NASDAQ
2. United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results
3. Cell Therapeutics Updates Shareholders on Trading
4. Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
5. Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
6. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST
7. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
8. Nile Therapeutics to Present at the 2009 BIO CEO & Investor Conference
9. Nile Therapeutics to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
11. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... MD, April 22, 2014: The Association for Molecular ... The Journal of Molecular Diagnostics on recommendations ... baccalaureate and master,s levels of education. The report ... Curriculum Task Force of the AMP Training and ... critical need of educating future medical laboratory scientists ...
(Date:4/22/2014)... German . ... but their mode of action is complex: In low ... behavior, while at high concentrations they can cause "oxidative ... how redox signaling unfolds in single cells and organelles ... developed jointly by the teams of LMU Professor Martin ...
(Date:4/22/2014)... we all seem to know who we say is neurotic ... isn,t unable to act but simply doesn,t want to., ... study of nearly 4,000 college students in 19 countries has ... decisions and moving forward with life. Turns out that when ... just don,t like it as much as non-neurotics. Therefore persuasive ...
(Date:4/22/2014)... This news release is available in German . ... F. Perutz Laboratories of the University of Vienna and the ... Zurich, have now shown how double stranded RNA, such as ... a cell. During the immune response against viral infection, the ... cytoplasm. There it modifies viral RNA to inhibit reproduction of ...
(Date:4/22/2014)... like toddlers, but their total brain size suggests ... or fox squirrel, according to a new study ... from orangutans to zebra finches. , Scientists at ... than two-dozen other research institutions collaborated on this ... defined in the study as the ability to ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Neuroimaging: Live from inside the cell 2Health News:Neurotics don't just avoid action: They dislike it 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3Health News:Brain size matters when it comes to animal self-control 2Health News:Brain size matters when it comes to animal self-control 3
... MedCom USA, Inc.,(OTC Bulletin Board: EMED), a leading ... for the healthcare industry,has signed a distribution agreement ... force, the product line of MedCom USA.,MedCom,s products ... options which include Credit/Debit, Easy Pay and Check,Guarantee/EFT ...
... Heart Association says high blood sugar condition linked to ... -- A national effort is needed to deal with ... says an American Heart Association scientific statement released Monday. ... about the condition, also known as hyperglycemia, in people ...
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... president of clinical research. In this newly,created position, ... and,oversight of Rigel,s clinical research programs in rheumatoid ... syk kinase,inhibitor, is expected to enter advanced Phase ...
... /Xinhua-PRNewswire-FirstCall/ -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS; ... the United States that operates Beijing Liang,Fang Pharmaceutical ... Pharmaceutical,Co., Ltd. both of which are pharmaceutical companies ... that it has raised $5 million in,a private ...
... NEW YORK, Feb. 26 , WHO: New York Lt. Gov. David A. Paterson, along with stem ... R. Lyon, M.D., will be the keynote speakers at the 3rd ... p.m. on Tuesday, February 26 ... Trianon Ballroom 1335 Avenue ...
... BMR, TORONTO, Feb. 26 /PRNewswire-FirstCall/ ... dedicated to the development and,commercialization of ... II data,on the Company,s Neuradiab product ... glioblastoma multiforme (GBM) were published in ...
Cached Medicine News:Health News:MedCom USA Signs Southwood Medical Marketing to Distribute MedCom System 2Health News:MedCom USA Signs Southwood Medical Marketing to Distribute MedCom System 3Health News:MedCom USA Signs Southwood Medical Marketing to Distribute MedCom System 4Health News:National Effort Needed to Address Hyperglycemia in Heart Patients 2Health News:Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research 2Health News:Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research 3Health News:Lotus Pharmaceuticals Raises $5 Million in Private Placement 2Health News:Lotus Pharmaceuticals Raises $5 Million in Private Placement 3Health News:MEDIA ADVISORY: New York Lt. Gov. David Paterson and Stem Cell Experts to Participate in 3rd Annual Stem Cell Summit 2Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 2Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 3Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 4
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... The VersaPulse® PowerSuite™ holmium laser combines ... for precise, virtually bloodless procedures. It ... urinary and gall bladder stones of ... multipurpose surgical tool. Because its laser ...
... laser combines excellent cutting, ablation and ... procedures. It is also extremely effective ... stones of all compositions, making it ... its laser light is transmitted through ...
... adjustable height permits optimal leg position for the ... a cast with the foot/ankle at 90 degrees ... the tongue of the stand. Stockinette is pulled ... plaster/fiberglass is used in a routine fashion. The ...
... Techno-Aide provides the highest level of ... quality lead protective eyewear. Consistent ... tolerance allowed. Mfg supervised by Licensed ... lens meet or exceed standards for ...
Medicine Products: